Spoken Alpha
URGN
UroGen Pharma Ltd.
Overview
UroGen Pharma develops and commercializes treatments for urothelial and specialty cancers using its proprietary RTGel sustained-release hydrogel technology.
UroGen Pharma Ltd is a Healthcare company operating in Biotechnology with a $2.11B market cap.
Most recent reported earnings: Q3 FY2026 (Nov 4, 2026).
21 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Management language signature
Disclosures
Investor Relations
Extracted from SEC 10-K filing, 2026-08-30.
Transcripts
Recent earnings calls
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
- Q1 FY2026Earnings2026-05-067 Q&A exchanges
- Q4 FY2025Earnings2026-03-0213 Q&A exchanges
- Q3 FY2025Earnings2025-11-069 Q&A exchanges
- Q2 FY2025Earnings2025-08-0914 Q&A exchanges
- Q1 FY2025Earnings2025-05-1218 Q&A exchanges
- Q4 FY2024Earnings2025-03-109 Q&A exchanges
- Q3 FY2024Earnings2024-11-0617 Q&A exchanges
- Q2 FY2024Earnings2024-08-1314 Q&A exchanges
- Q1 FY2024Earnings2024-05-1310 Q&A exchanges
- Q4 FY2023Earnings2024-03-1413 Q&A exchanges
- Q3 FY2023Earnings2023-11-1410 Q&A exchanges
- Q2 FY2023Earnings2023-08-108 Q&A exchanges
- Q1 FY2023Earnings2023-05-1115 Q&A exchanges
- Q4 FY2022Earnings2023-03-1618 Q&A exchanges
- Q3 FY2022Earnings2022-11-1030 Q&A exchanges
- Q2 FY2022Earnings2022-08-1112 Q&A exchanges
- Q1 FY2022Earnings2022-05-1023 Q&A exchanges
- Q4 FY2021Earnings2022-03-2114 Q&A exchanges
- Q3 FY2021Earnings2021-11-1513 Q&A exchanges
- Q2 FY2021Earnings2021-08-0718 Q&A exchanges
- Q1 FY2021Earnings2021-05-1323 Q&A exchanges
History
Earnings history
- Q3 FY20262026-11-04EPS— vs $0.38—Rev— vs ——EODHD
- Q2 FY20262026-08-04EPS$-0.28 vs $-0.38+26.3%Rev$72.5M vs ——EODHD
- Q1 FY20262026-05-05EPS$-0.47 vs $-0.48+2.1%Rev$51.0M vs ——EODHD
- Q4 FY20252026-03-01EPS$-0.53 vs $-0.48-9.9%Rev$37.8M vs ——EODHD
- Q3 FY20252025-11-05EPS$-0.69 vs $-0.68-1.5%Rev$27.5M vs ——EODHD
- Q2 FY20252025-08-06EPS$-1.05 vs $-0.82-28.1%Rev$24.2M vs ——EODHD
- Q1 FY20252025-05-11EPS$-0.92 vs $-0.79-16.5%Rev$20.3M vs ——EODHD
- Q4 FY20242025-03-11EPS$-0.80 vs $-0.72-11.1%Rev$24.6M vs ——EODHD
- Q3 FY20242024-11-05EPS$-0.55 vs $-0.82+32.9%Rev$25.2M vs ——EODHD
- Q2 FY20242024-08-12EPS$-0.91 vs $-0.83-9.6%Rev$21.8M vs ——EODHD
- Q1 FY20242024-05-12EPS$-0.97 vs $-0.87-11.5%Rev$18.8M vs ——EODHD
- Q4 FY20232024-03-13EPS$-0.72 vs $-0.68-5.9%Rev$23.5M vs ——EODHD
- Q3 FY20232023-11-13EPS$-0.68 vs $-0.87+21.8%Rev$20.9M vs ——EODHD
- Q2 FY20232023-08-09EPS$-1.03 vs $-1.14+9.7%Rev$21.1M vs ——EODHD
- Q1 FY20232023-05-10EPS$-1.30 vs $-1.24-4.8%Rev$17.2M vs ——EODHD
- Q4 FY20222023-03-15EPS$-1.22 vs $-1.07-14.0%Rev$18.1M vs ——EODHD
- Q3 FY20222022-11-09EPS$-1.13 vs $-1.14+0.9%Rev$16.1M vs ——EODHD
- Q2 FY20222022-08-10EPS$-1.18 vs $-1.33+11.3%Rev$16.6M vs ——EODHD
- Q1 FY20222022-05-09EPS$-1.25 vs $-1.250.0%Rev$13.6M vs ——EODHD
- Q4 FY20212022-03-20EPS$-1.27 vs $-1.17-8.6%Rev$16.2M vs ——EODHD
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2026 | 2026-11-04 | — | $0.38 | — | — | — | — | EODHD |
| Q2 FY2026 | 2026-08-04 | $-0.28 | $-0.38 | +26.3% | $72.5M | — | — | EODHD |
| Q1 FY2026 | 2026-05-05 | $-0.47 | $-0.48 | +2.1% | $51.0M | — | — | EODHD |
| Q4 FY2025 | 2026-03-01 | $-0.53 | $-0.48 | -9.9% | $37.8M | — | — | EODHD |
| Q3 FY2025 | 2025-11-05 | $-0.69 | $-0.68 | -1.5% | $27.5M | — | — | EODHD |
| Q2 FY2025 | 2025-08-06 | $-1.05 | $-0.82 | -28.1% | $24.2M | — | — | EODHD |
| Q1 FY2025 | 2025-05-11 | $-0.92 | $-0.79 | -16.5% | $20.3M | — | — | EODHD |
| Q4 FY2024 | 2025-03-11 | $-0.80 | $-0.72 | -11.1% | $24.6M | — | — | EODHD |
| Q3 FY2024 | 2024-11-05 | $-0.55 | $-0.82 | +32.9% | $25.2M | — | — | EODHD |
| Q2 FY2024 | 2024-08-12 | $-0.91 | $-0.83 | -9.6% | $21.8M | — | — | EODHD |
| Q1 FY2024 | 2024-05-12 | $-0.97 | $-0.87 | -11.5% | $18.8M | — | — | EODHD |
| Q4 FY2023 | 2024-03-13 | $-0.72 | $-0.68 | -5.9% | $23.5M | — | — | EODHD |
| Q3 FY2023 | 2023-11-13 | $-0.68 | $-0.87 | +21.8% | $20.9M | — | — | EODHD |
| Q2 FY2023 | 2023-08-09 | $-1.03 | $-1.14 | +9.7% | $21.1M | — | — | EODHD |
| Q1 FY2023 | 2023-05-10 | $-1.30 | $-1.24 | -4.8% | $17.2M | — | — | EODHD |
| Q4 FY2022 | 2023-03-15 | $-1.22 | $-1.07 | -14.0% | $18.1M | — | — | EODHD |
| Q3 FY2022 | 2022-11-09 | $-1.13 | $-1.14 | +0.9% | $16.1M | — | — | EODHD |
| Q2 FY2022 | 2022-08-10 | $-1.18 | $-1.33 | +11.3% | $16.6M | — | — | EODHD |
| Q1 FY2022 | 2022-05-09 | $-1.25 | $-1.25 | 0.0% | $13.6M | — | — | EODHD |
| Q4 FY2021 | 2022-03-20 | $-1.27 | $-1.17 | -8.6% | $16.2M | — | — | EODHD |
Source: EODHD. URGN reported actuals as published; sparse fields render as —.
Top executives
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
Peers
Other companies in Healthcare
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
For developers and AI agents
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for URGN.
$ curl https://api.spokenalpha.com/v1/companies/URGNFAQ
Frequently asked about URGN
Where can I find UroGen Pharma Ltd.'s (URGN) earnings call transcripts?
Spoken Alpha indexes URGN's earnings call transcripts at https://spokenalpha.com/companies/URGN. Each call links to attributed speakers and parsed analyst Q&A. UroGen Pharma Ltd.'s own investor relations page is at https://investors.urogen.com/.
When was UroGen Pharma Ltd.'s most recent earnings call?
UroGen Pharma Ltd. (URGN) held its most recent earnings call on 2026-05-06, covering fiscal Q1 2026.
What sector is URGN in?
UroGen Pharma Ltd. (URGN) operates in the Healthcare sector (Biotechnology industry).